A Phase 1b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Multiple Subcutaneous Doses of OLP-1002 in Patients Who Have Pain Due to Moderate to Severe Osteoarthritis in a Hip and/or Knee Joint
Latest Information Update: 21 Nov 2023
At a glance
- Drugs OLP 1002 (Primary)
- Indications Musculoskeletal pain
- Focus Adverse reactions
- Sponsors OliPass
- 13 Nov 2023 According to an OliPass Corporation media release, the trial was conducted in Australia again with Novotech. The efficacy readouts are available.
- 13 Nov 2023 Results presented in an OliPass Corporation media release.
- 23 Dec 2020 Status changed from recruiting to completed.